11h
GlobalData on MSNRegeneron’s macular oedema therapy shows promise in Phase III trialIn the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.
Older women could be vulnerable to harmful inflammation from new gene therapies to treat incurable eye diseases, new research has found.
Macular degeneration is a condition that affects the retina, which is neural tissue that lines the back of the eye, like wallpaper in a room. There is an important area ...
Regeneron Pharmaceuticals Inc. (REGN) announced positive three-year (156-week) results for EYLEA HD (aflibercept) Injection 8 mg in ...
From her Oscar-winning turn as Queen Elizabeth I in Shakespeare in Love to her famously gender-swapped role as "M" in the ...
Our eyesight is essential to getting around, but if you’re not careful it can be seriously challenged by age-related macular degeneration.
Age-related macular degeneration is an eye disease caused by a problem with the retina ... New treatment options for AMD may be on the horizon. For example, researchers are currently studying the ...
EYE-103 is under clinical development by Eyebiotech and currently in Phase III for Diabetic Macular Edema. According to GlobalData, Phase III drugs for Diabetic Macular Edema have a 62% phase ...
Judi Dench can no longer see on film sets due to her macular degeneration eye condition. The 90-year-old actress appeared on British entrepreneur Trinny Woodall’s “Fearless” podcast last wee ...
A vision technology startup has developed a pair of smart glasses that clear up spotty vision. Designed for people experiencing macular degeneration—the leading cause of vision loss among people ...
"All the systems of the body are represented, so as well as all the eye diseases that we look for – cataracts, glaucoma, macular degeneration, problems with vision – we an also detect things ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results